Science
FDA rule would replace animal test references with nonclinical tests
Hacker News reports that the FDA has moved to make animal studies the exception, with a September 2026 rule pending.
The short version
- The FDA issued a September 2026 rule that, if it takes effect, replaces 'animal tests' with 'nonclinical tests' in drug-development regulations.[Hacker News]
- The rule would explicitly allow validated alternatives such as human-cell systems, organs-on-chips and computer models where appropriate.[Hacker News]
- It follows a late-2022 law authorizing alternatives in preclinical drug studies and a 2025 FDA pledge to make animal studies the exception.[Hacker News]
- Whether the rule takes effect remains the key open question.[Hacker News]
Key facts
- Science initially rejected the lung-on-a-chip paper from Donald Ingber's Harvard Wyss Institute team, which later ran the requested mouse experiments and published the study in 2010.[Hacker News]
- The lung-on-a-chip is smaller than a USB stick and is lined with human lung air-sac cells and blood-vessel endothelial cells.[Hacker News]
- The FDA Modernization Act 2.0 became law in late 2022, explicitly authorizing alternatives in preclinical studies required before new drugs enter human trials.[Hacker News]
- In 2025 the FDA pledged to make animal studies the exception rather than the norm for drug safety testing.[Hacker News]
- In September 2026 the FDA issued a rule that, if it takes effect, replaces 'animal tests' with 'nonclinical tests' in drug-development regulations.[Hacker News]
What remains uncertain
- Whether the September 2026 FDA rule takes effect is unresolved, since the reporting describes it as applying only if it takes effect.[Hacker News]
- The reporting does not quantify how widely alternatives have replaced animal testing in practice.[Hacker News]
Sources
Outlet counts describe coverage, not independent confirmation. Reports may share a wire service or original source.